HIV market stalwart Gilead Sciences Inc. is once again positioned for huge success with its recently launched single-tablet regimen Biktarvy (BIC/F/TAF), but competitor ViiV Healthcare still could emerge as the market leader over the next decade, Datamonitor Healthcare analysts conclude.
The US FDA approved Gilead's Biktarvy, which combines the integrase inhibitor bictegravir, the nucleoside reverse transcriptase inhibitorEmtriva (emtricitabine) and the second-generation nucleoside reverse transcriptase inhibitor tenofovir alafenamide (TAF), for initial or replacement
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?